Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of β-Cell Replacement.

Transplantation

1 Division of Transplantation, Massachusetts General Hospital, Boston, MA. 2 Department of Surgery, University of Maryland School of Medicine, Baltimore, MD. 3 Nuffield Department of Surgical Sciences and Oxford Centre for Diabetes, Endocrinology, and Metabolism, University of Oxford, Oxford, United Kingdom. 4 Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. 5 Schulze Diabetes Institute, Department of Surgery, University of Minnesota, Minneapolis, MN. 6 Prodo Laboratories, LLC, Irvine, CA. 7 The Scharp-Lacy Research Institute, Irvine, CA. 8 St. Vincent's Institute of Medical Research, Victoria, Australia. 9 Department of Medicine, St. Vincent's Hospital, The University of Melbourne, Victoria, Australia. 10 Division of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI. 11 Joslin Diabetes Center and Harvard Medical School, Boston MA. 12 National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD. 13 Division of Transplantation, University of San Francisco Medical Center, San Francisco, CA. 14 Department of Surgery, Fukushima Medical University, Fukushima, Japan. 15 Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA. 16 Xenotransplantation Research Center, Department of Microbiology and Immunology, Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea. 17 The Center for Transplant and Renal Research, Westmead Millennium Institute, University of Sydney at Westmead Hospital, Westmead, NSW, Australia. 18 Department of Biomedical Engineering, University of Florida, Gainesville, FL. 19 Otsuka Pharmaceutical Factory inc, Naruto Japan. 20 National Center for Global Health and Medicine, Tokyo, Japan. 21 Department of Medicine III, Technische Universität Dresden, Dresden, Germany. 22 Paul Langerhans Institute Dresden of Helmholtz Centre Munich at University Clinic

Published: July 2016

The International Pancreas and Islet Transplant Association (IPITA), in conjunction with the Transplantation Society (TTS), convened a workshop to consider the future of pancreas and islet transplantation in the context of potential competing technologies that are under development, including the artificial pancreas, transplantation tolerance, xenotransplantation, encapsulation, stem cell derived beta cells, beta cell proliferation, and endogenous regeneration. Separate workgroups for each topic and then the collective group reviewed the state of the art, hurdles to application, and proposed research agenda for each therapy that would allow widespread application. Herein we present the executive summary of this workshop that focuses on obstacles to application and the research agenda to overcome them; the full length article with detailed background for each topic is published as an online supplement to Transplantation.

Download full-text PDF

Source
http://dx.doi.org/10.1097/TP.0000000000001054DOI Listing

Publication Analysis

Top Keywords

executive summary
8
pancreas islet
8
summary ipita-tts
4
ipita-tts opinion
4
opinion leaders
4
leaders report
4
report future
4
future β-cell
4
β-cell replacement
4
replacement international
4

Similar Publications

Review of Indian studies on environmental impact assessment.

Integr Environ Assess Manag

January 2025

Department of Architecture and Planning, National Institute of Technology Patna, Patna, India.

Environmental clearance in India is a legal instrument that determines potential environmental implication of organized projects in India. It entails an assessment of sensitive projects, focal points, and proposals that have potential and likely effects on social, environmental, and economic matters before they are commenced. The intended goal of this procedure is to detect negative effects on local societies, the environment in this case, so as to foster sustainable development.

View Article and Find Full Text PDF

Nationwide guideline implementation: a qualitative study of barriers and facilitators from the perspective of guideline organizations.

BMC Health Serv Res

January 2025

Amsterdam UMC, Department of Public and Occupational Health, Vrije Universiteit Amsterdam, Amsterdam Public Health research institute, Van der Boechorststraat 7, NL-1081 BT, Amsterdam, The Netherlands.

Background: Although the number of Dutch guidelines is growing, their uptake and impact in clinical practice lag behind. Dutch guideline organizations, including guideline developers, governmental agencies, health insurers and other national organizations, play a crucial role in developing, authorizing and/or supporting the use of guidelines. They influence end users' awareness, accessibility, understanding, acceptability and applicability of guidelines.

View Article and Find Full Text PDF

Background: Individuals with first-episode psychosis (FEP) face an increased risk of physical comorbidities, notably cardiovascular diseases, metabolic disorders, respiratory disorders, and certain types of cancer. Previous reviews report pooled physical health prevalence from chronic psychosis and FEP groups. By contrast, this review will focus on antipsychotic-naïve FEP cohorts and incorporate data from observational longitudinal studies and antipsychotic intervention studies to understand the progression of physical health comorbidities from the onset to later stages of psychosis.

View Article and Find Full Text PDF

Patients after thoracic surgery experience significant pain that can disrupt normal respiratory mechanics, increase the risk of respiratory complications, and impair recovery. Poorly controlled postoperative pain can develop into persistent postoperative pain. In addition, using opioids for pain control in the thoracic surgical population makes them more susceptible to opioid-related side effects due to their pre-existing comorbidities.

View Article and Find Full Text PDF

Basic Considerations for Data Pooling Strategy in Multi-Regional Clinical Trials (MRCTs).

Ther Innov Regul Sci

January 2025

Department of Biostatistics, School of Public Health, Peking University, Beijing, China.

The National Medical Products Administration of China has been implementing ICH E17, which describes the general principles for planning and designing of multi-regional clinical trials (MRCTs), yet there are several ambiguities in the execution and conduct remains in China or East Asia. In specific, pooling strategy, effect modifiers (EMs), statistical analysis, sample size allocation and their impact in alignment with global trial remains a challenge. In this paper, we explore on the criteria mentioned above under the context of China.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!